Antithrombotic Drug Therapy in Cardiovascular Disease (Record no. 916)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04970nam a22001817a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 210624b |||||||| |||| 00| 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 978-1-60327-234-6 |
| International Standard Book Number | 978-1-60327-235-3 |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Askari, Arman. T |
| 9 (RLIN) | 16188 |
| 245 ## - TITLE STATEMENT | |
| Title | Antithrombotic Drug Therapy in Cardiovascular Disease |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | London |
| Name of publisher, distributor, etc. | Humana Press, a part of Springer Science+Business Media, LLC |
| Date of publication, distribution, etc. | 2010 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 463 Pages |
| 500 ## - GENERAL NOTE | |
| General note | Includes Index |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | It is now well established that pathologic thrombosis plays a central role in the pathogenesis of<br/>acute coronary syndromes (ACS), ischemic complications of percutaneous coronary intervention<br/>(PCI), venous thromboembolic disease, and embolic complications of arrhythmias and various cardiomyopathies. Born out of the understanding of the integral role of thrombus formation across the<br/>spectrum of cardiovascular diseases is the burgeoning field of antithrombotic therapies. Rigorous<br/>investigation of individual or various combinations of the available antithrombotic regimens including<br/>fibrinolytic agents, antiplatelet therapies (aspirin, the thienopyridines, glycoprotein IIb/IIIa inhibitors), and anticoagulant therapies (unfractionated heparin, low-molecular-weight heparins, direct<br/>thrombin inhibitors, and synthetic factor X inhibitors) has lead to a marked improvement in outcomes<br/>for patients with a thrombotic event. Nevertheless, a substantial morbidity and mortality remains<br/>associated with these thrombotic events. This realization has fueled the rapid expansion of the available armamentarium to combat pathologic thrombosis.<br/>Antithrombotic Drug Therapy in Cardiovascular Disease will serve as a resource for individuals<br/>charged with caring for patients across the spectrum of cardiovascular diseases. This text is a comprehensive, up-to-date overview of the pathophysiology, including the genetics, of arterial and venous<br/>thrombosis followed by detailed overviews of the use of antithrombotic therapies for managing<br/>patients with various thrombotic disorders. Antithrombotic Drug Therapy in Cardiovascular Disease,<br/>a compilation of work by thought leaders in the field, is broken down into seven parts which will<br/>provide rapid access to various therapies used for each of the major classes of thrombotic disorders<br/>commonly encountered by clinicians.<br/>The first part of Antithrombotic Drug Therapy in Cardiovascular Disease is comprised of four<br/>chapters that will provide a comprehensive overview of the basic principles of thrombosis. Chapters<br/>1 and 2 review the key components of thrombosis, the platelet and the coagulation cascade, respectively. Chapter 3 then develops the link between inflammation, a process demonstrated to be involved<br/>in atherogenesis, and thrombosis. Chapter 4 then provides a comprehensive view of the genetics of<br/>thrombosis.<br/>Parts II–IV then provide data and clinical recommendations for the use of antithrombotic therapies<br/>for common atherothrombotic disorders including stable coronary artery disease (Part II, Chaps. 5 and<br/>6), non-ST-segment elevation (NSTE) ACS (Part III, Chaps. 7–10), and ST-segment elevation myocardial infarction (STEMI) (Part IV, Chaps. 11–13).<br/>Part V provides data and recommendation for the use of various antithrombotic therapies as<br/>adjuncts to interventional procedures. Chapter 14 focuses on the use of antithrombotic therapies for<br/>PCI, while Chapter 15’s focus is on carotid and peripheral interventions. Chapter 16 will provide a<br/>detailed review of monitoring of the various antithrombotic therapies in the peri-interventional<br/>period.<br/>Part VI focuses on venous thromboembolic diseases. This part of Antithrombotic Drug Therapy in<br/>Cardiovascular Disease will provide the data necessary to manage patients with deep vein thrombosis<br/>(DVT) and pulmonary embolism (PE) in an evidence-based fashion. Chapter 17 focuses on prophylaxis |
| Expansion of summary note | and treatment for patients with DVT/PE. Chapter 18 synthesizes the data on the use of fibrinolysis for<br/>PE. Chapter 19 completes the section with a detailed, yet concise overview of the recommended durations of therapy for patients with venous thromboembolic diseases.<br/>The final part of Antithrombotic Drug Therapy in Cardiovascular Disease provides detailed overviews of the use of antithrombotic therapies in several clinical conditions commonly encountered in<br/>the field of cardiology including atrial fibrillation (Chap. 20), valvular heart disease (Chap. 21), and<br/>cardiomyopathy (Chap. 22). Chapter 23 focuses on the pathophysiology and management of heparininduced thrombocytopenia. Finally, an analysis of the increasingly encountered scenario of aspirin<br/>and clopidogrel resistance will be addressed in Chapter 24.<br/>In summary, this textbook will provide detailed, up-to-date data regarding the use of the currently<br/>available antithrombotic therapies for commonly encountered clinical situations in cardiology. |
| 654 ## - SUBJECT ADDED ENTRY--FACETED TOPICAL TERMS | |
| General subdivision | Cardiology |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 16189 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | ddc |
| Koha item type | E-BOOKS |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Collection | Home library | Current library | Shelving location | Date acquired | Total checkouts | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | 06/24/2021 | EBS5358 | 06/24/2021 | 06/24/2021 | E-BOOKS |